2005 Fiscal Year Final Research Report Summary
Clinical trial of the tailor-made medication for the treatment of prostate cancer by estramustine phosphate sodium.
| Project/Area Number |
15390485
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
KITAMURA Tadaichi The University of Tokyo, Faculty of Medicine, Professor, 医学部附属病院, 教授 (70010551)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOMITA Kyoichi The University of Tokyo, Faculty of Medicine, Associate professor, 医学部附属病院, 助教授 (20272578)
KUME Haruki The University of Tokyo, Faculty of Medicine, Lecturer, 医学部附属病院, 講師 (10272577)
NISHIMATSU Hiroaki The University of Tokyo, Faculty of Medicine, Lecturer, 医学部附属病院, 講師 (60251295)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Keywords | Single nucleotide polymorphism / Estramustine phosphate sodium / Prostate cancer / Tailor-made medication / 17β-hydroxysteroid dehydrogenase / Catechol-O-methyltransferase / Cytochrome P450 1A1 |
|---|
| Research Abstract |
In this study, we had prompted to study the interindividual differences of efficacy and adverse effects of estramustine phosphate sodium (EMP) for the treatment of previously untreated advanced prostate cancer. At first, we evaluated clinical efficacy of a low-dose EMP therapy. A low-dose EMP therapy achieved good clinical outcome and reduced toxicities in a dose depend manner. Secondary, we analyzed single nucleotide polymorphisms (SNPs) in the 17β-hydroxysteroid dehydrogenase and the cytochrome P450 (GYP) 1A1 genes, which are involved in the metabolism of EMP. We revealed these SNPs are related with peripheral edema and gastrointestinal toxicity. Furthermore, we found that the Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression free survival in prostate cancer patients treated with EMP. Nowadays, prior to starting EMP therapy, we actually predict the risk of gastrointestinal toxicity by genotyping of the CYP1A1 gene to perform a tailor-made medication with EMP.
|
Research Products
(21 results)
-
-
-
-
-
-
[Journal Article] the vall58Met Polymorphism of the Catechol-O-methyltransferase Gene is associated with the PSA-Progression-Free Survival in Prostate Cancer Patients treated with Estramustine phosphate2005
Author(s)
Suzuki M, Mohammed R, Hara K, Ozeki T, Yamada Y, Kadowaki T, Honda H, Yanagihara Y, Ito M Y, Kameyama S, Ohta N, Hosoi T, Arai T, Sawade M, Takwuchi T, Takahashi S, Kitamura T
-
Journal Title
Eur Urol 48
Pages: 752-759
Description
「研究成果報告書概要(和文)」より
-
[Journal Article] Incidence of gastrointestinal toxicity during estramustine phosphate therapy for prostate cancer is associated with the single-nucleotide polymorphisms in the cytochrome P450 lAl(CYPlAl) gene2005
Author(s)
Mohammed R, Suzuki M, Takahashi S, Hara K, Ozeki T, Yamada Y, kadowaki T, Yanagihara Y, Kameyama S, Ito M Y, Takeuchi T, Kitamura T
-
Journal Title
Cancer Therapy 3
Pages: 525-530
Description
「研究成果報告書概要(和文)」より
-
-
-
-
[Journal Article] The Val158Met Polymorphism of the Catechol-O-methyltransferase Gene is associated with the PSA-Progression-Free Survival in Prostate Cancer Patients treated with Estramustine phosphate2005
Author(s)
Suzuki M, Mohammed R, Hara K, Ozeki T, Yamada Y, Kadowaki T, Honda H, Yanagihara Y, Ito M Y, Kameyama S, Ohta N, Hosoi T, Arai T, Sawabe M, Takeuchi T, Takahashi S, Kitamura T.
-
Journal Title
Eur Urol 48
Pages: 752-759
Description
「研究成果報告書概要(欧文)」より
-
[Journal Article] Incidence of gastrointestinal toxicity during estramustine phosphate therapy for prostate cancer is associated with the single-nucleotide polymorphisms in the cytochrome P450 1A1 (CYP1A1) gene2005
Author(s)
Mohammed R, Suzuki M, Takahashi S, Hara K, Ozeki T, Yamada Y, Kadowaki T, Yanagihara Y, Kameyama S, Ito M Y, Takeuchi T, Kitamura T
-
Journal Title
Cancer Therapy 3
Pages: 525-530
Description
「研究成果報告書概要(欧文)」より
-
-
-
-
-
-
-
-
-
